Pharmaceutical TechnologyOriginal article
FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
RegulatoryGazyva/GazyvaroPositive
AI Analysis
Summary
The FDA has granted priority review to Roche's supplemental BLA for Gazyva/Gazyvaro in the treatment of adults with primary membranous nephropathy, indicating expedited regulatory evaluation.
Outcome Details
Priority review granted for supplemental BLA
Importance:7/10
Sentiment:
0.70
FDAPriority ReviewsBLAGazyvaGazyvaroNephropathy
Related Companies
Read the original article
Published by Pharmaceutical Technology on July 15, 2026 9:50 AM